Opinion|Videos|May 30, 2024
Aligning With 2023 ESC Guidelines in oHCM Treatment
Author(s)Anjali Tiku Owens, MD
Anjali Tiku Owens, MD, explores the role of cardiac myosin inhibitors in the treatment strategies for patients with obstructive hypertrophic cardiomyopathy (oHCM), in accordance with the latest European Society of Cardiology (ESC) Guidelines released in 2023.
Advertisement
Episodes in this series
- Where do cardiac myosin inhibitors fit into the treatment plans of your patients with oHMC, according to the most recent guidelines?
ESC Guidelines 2023
- Initiating cardiac myosin inhibitors earlier?
- Use in patients who are severely symptomatic?
- MAPLE-HCM trial
Advertisement
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Two-year ICONIC-LEAD data show oral icotrokinra sustained PASI 90 and IGA 0/1 responses in more than 70% of adults and adolescents with plaque psoriasis.
New TOGETHER-PsO data show ixekizumab plus tirzepatide drove broader immune and metabolic biomarker changes than ixekizumab alone in psoriasis and obesity.
Jasmohan Bajaj, MD, joins Nancy Reau, MD, and Kim Brown, MD, to review what is new in the ACG hepatic encephalopathy guideline.
Lasker Award winners Takehisa Kitazawa and Tomoyuki Igawa discuss prophylaxis gains, remaining unmet needs, and lessons for drug discovery.
In the phase 3 RAPIDe-3 trial published in The Lancet, median time to symptom relief was 1.28 hours with deucrictibant vs more than 12 hours with placebo.
Lasker Award winners Kunihiro Hattori, Takehisa Kitazawa, and Tomoyuki Igawa recount the 2400 variants behind the drug.
Weltruza requires no loading doses, oral supplementation, or post-injection monitoring, with approval based on the phase 3 SOLARIS trial.
Advertisement
Advertisement
Trending on HCPLive
1
Tilrekimig Meets EASI-75 Goal in Atopic Dermatitis, With Eric Simpson, MD
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
Tips on Optimizing HS Biologics, Combinations, and Surgery
4
Why "Normal" Ferritin Can Miss Iron Deficiency, With Jacquelyn Powers, MD, MS
5